March 29th 2023
Investigators are assessing tirabrutinib, which received orphan drug designation from the FDA, as a treatment for patients with relapsed or refractory primary central nervous system lymphoma in the phase 2 PROSPECT study.
Zandelisib/Zanubrutinib Combination in R/R CLL and B-Cell Malignancies Shows Clinical Benefit
June 12th 2021Phase 1 data presented at 2021 EHA indicate that a high rate of response was associated with zandelisib plus zanubrutinib therapy in patients with relapsed/refractory B-cell malignancies and chronic lymphocytic leukemia.
Thiotepa Conditioning Regimens Improve Survival in Primary Central Nervous System Lymphoma
May 18th 2021An observational cohort study revealed that BEAM therapy led to subpar outcomes compared with thiotepa-based treatment for patients requiring conditioning regimens for primary central nervous system lymphoma.
Allogeneic CAR T-Cell Product Shows Early Promise for Patients With CD30+ Lymphomas
May 17th 2021An off-the-shelf cellular therapy that combines Epstein Barr Virus–Specific T cells and a CD30-targeting chimeric antigen receptor product demonstrated safety and early efficacy in a group of patients with CD30-positive lymphomas.
Real-World Data Suggest Systemic High-Dose and Intrathecal MTX Lower CNS Relapse Incidence for DLBCL
May 7th 2021The 3-year follow-up analysis of 4 treatment groups who received CNS prophylaxis found a decreased incidence of CNS relapse for patients with high-risk diffuse large B-cell lymphoma, although the data were not statistically significant.
Matthew J. Matasar, MD, on the Clinical Implications of the Phase 3 CHRONOS-3 Study
April 27th 2021The lymphoma expert discussed how adding copanlisib to rituximab improved progression-free survival, while demonstrating a manageable safety profile in patients with relapsed indolent non-Hodgkin lymphoma.
Lenalidomide Plus R-CHOP Did Not Improve PFS Compared With Placebo Plus R-CHOP for ABC-Type DLBCL
April 8th 2021Even though the safety profile remained tolerable, treatment with lenalidomide plus R-CHOP did not improve progression-free survival compared with placebo plus R-CHOP for patients with activated B-cell-like subtype of DLBCL.
Umbralisib Activity, Safety in Indolent Lymphomas Demonstrated in Phase 2b Trial
April 6th 2021Data that led to the approval of umbralisib in patients with indolent non-Hodgkin lymphoma— including follicular lymphoma and marginal zone lymphoma—indicates favorable activity of the therapy versus other available PI3K inhibitors.